Piper Jaffray Believes Antares Pharma (NASDAQ: ATRS) Still Has Room to Grow

By Ryan Adsit

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS) yesterday and set a price target of $4. The company’s shares closed yesterday at $3.18, close to its 52-week high of $3.37.

According to TipRanks.com, Amsellem is a 3-star analyst with an average return of 1.1% and a 49.6% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Amphastar Pharmaceuticals, and Supernus Pharmaceuticals.

Antares Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

Based on Antares Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $12.01 million and GAAP net loss of $4.74 million. In comparison, last year the company earned revenue of $12.23 million and had a GAAP net loss of $6.06 million.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies.